跳至主要内容
临床试验/NCT05049707
NCT05049707尚未招募3 期

Does Perioperative Intravenous Magnesium Affect Postoperative Quality of Recovery in Elective Craniotomy Surgery Patients?

Thomas Jefferson University0 个研究点目标入组 110 人开始时间: 2024年11月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
尚未招募
入组人数
110
主要终点
Quality of Recovery Questionnaire 40

研究概览

简要总结

Perioperative pain management for craniotomy patients may be challenging because the commonly used agents such as opioids, gabapentin, and dexmedetomidine also cause sedation, which can confound the neurological exam and can lead to respiratory depression and increased intracranial pressure. Preoperative intravenous magnesium boluses and infusions have previously been established as an effective, nonsedating analgesic that can reduce opioid consumption 25-30% up to 48 hours postoperatively.

However, intravenous magnesium has not seen widespread use in craniotomy patients due to concerns for interference with the neurological monitoring that commonly occurs in these cases. Intravenous magnesium given as a bolus preoperatively or as a constant infusion may avoid these problems and has never been investigated.

The goal of this study is to compare intravenous magnesium given preoperatively and intraoperatively to placebo in adult elective craniotomy patients to improve quality of recovery postoperatively, and evaluate safety and tolerability. Secondary endpoints will include evaluating for pain, sedation, agitation, blood pressure, and opioid consumption postoperatively.

详细描述

The study is a prospective, randomized, controlled, and double-blinded clinical trial comparing clinical outcomes of craniotomy patients who a magnesium infusion of 15mg/kg/hr to a placebo group of patients who will receive a saline bolus and infusion of equivalent volume starting at surgical closure and continuing for 15 hours. The sample size calculations are based on an effect size 24 point increase in Quality of Recovery-40 Questionnaire scores from a previous randomized control trial featuring the same bolus and infusion regimen as this trial. Investigators, patients, and providers will be blinded. Patients over the age of 18 undergoing elective craniotomy surgery will be enrolled.

The study population will consist of patients undergoing elective craniotomy surgery. The inclusion criteria consists of patient age 18-85, ASA (American Society of Anesthesiologists) Physical Status Classification 1-3, with Glasgow Coma Scale (GCS) of 15 with adequate english comprehension. Exclusion criteria includes pregnant or nursing patients, patients with known allergies to any of the study drugs, patient's refusal, patients with a history of cirrhosis, chronic kidney disease stage 3 or higher, known history of substance abuse, neuromuscular disease or heart block.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Care Provider, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patient age 18-85
  • ASA (American Society of Anesthesiologists) Physical Status Classification 1-3
  • Glasgow Coma Scale (GCS) of 15
  • Adequate english comprehension

排除标准

  • pregnant or nursing patients
  • patients with known allergies to any of the study drugs
  • patient's refusal
  • patients with a history of cirrhosis
  • chronic kidney disease stage 3 or higher
  • known history of substance abuse
  • history of neuromuscular disease
  • history of heart block

研究组 & 干预措施

Control

Placebo Comparator

The control arm will receive an equivalent volume of normal saline as the treatment group

干预措施: Placebo (Other)

IV magnesium

Experimental

We will randomize patients in the treatment group to receive either a 50 mg/kg bolus of intravenous magnesium preoperatively followed by a magnesium infusion of 15mg/kg/hr, to be given after intraoperative neuromonitoring staff have been able to record baseline neurological data.

干预措施: IV magnesium sulfate (Drug)

结局指标

主要结局

Quality of Recovery Questionnaire 40

时间窗: Postoperative days 0-2

Validated measure of postoperative quality of recovery

次要结局

  • Hypertension Postoperative(postoperative days 0-2)
  • Postoperative Hyperglycemia(Postoperative days 0-2)
  • Complications Possibly Related to Intraoperative Neuromonitoring(postoperative days 0-2)
  • Shivering(First 2 hours in the postoperative care unit or intensive care unit)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Kevin Min

Assistant Professor of Anesthesiology

Thomas Jefferson University

相似试验